Downer EDI Limited (ASX:DOW) Awarded $500M Chorus FSA
Downer EDI Limited (ASX:DOW) has secured a $500 million Field Services Agreement with Chorus NZ, expanding their telecommunications services.
Tag: Industry-Specific News
ECS Botanics Holdings Ltd (ASX:ECS) Reports Half-Year Financial Results
ECS Botanics Holdings Ltd (ASX:ECS) reports a $1.98m net loss and strategic expansions in export markets and product offerings.
Traffic Technologies Ltd (ASX:TTI) Secures $0.8m Martha Cove Smart City Contract
Traffic Technologies Ltd (ASX:TTI) wins a $0.8m contract to install Smart City systems and LED tunnel lighting at Martha Cove, Victoria.
Golden Cross Resources Ltd (ASX:GCR) Begins New Sampling at Copper Hill
Golden Cross Resources Ltd (ASX:GCR) initiates infill and extension soil sampling at Copper Hill to enhance exploration efforts.
Aeris Resources Limited (ASX:AIS) Reports Strong HY25 Financial Results
Aeris Resources Limited (ASX:AIS) reports a 257% increase in net profit and strong cash flow in its FY25 half-year results.
Connected Minerals Limited (ASX:CML) Announces High-Grade Uranium Mineralisation at Etango North-East Project
Connected Minerals Limited (ASX:CML) confirms high-grade uranium mineralisation in its Etango North-East Project, highlighting exploration success and future drilling plans.
Hammer Metals Ltd (ASX:HMX) Commences IOCG Drilling at Bullrush JV
Hammer Metals Ltd (ASX:HMX) begins a 2,000m IOCG drilling program at Bullrush Joint Venture with Sumitomo Metal Mining Oceania.
Telix Pharmaceuticals Limited (ASX:TLX) FDA Accepts BLA for TLX250-CDx
Telix Pharmaceuticals (ASX:TLX) announces FDA acceptance of BLA for TLX250-CDx, targeting kidney cancer imaging with a planned U.S. launch in 2025.
Lynas Rare Earths Ltd (ASX:LYC) Reports H1 2024 Financial Results
Lynas Rare Earths Ltd (ASX:LYC) reports an 8% revenue increase in H1 2024, alongside key operational milestones and strong safety performance.
OncoSil Medical Ltd (ASX:OSL) Delivers Key Milestones and Financial Growth in H1 2025
OncoSil Medical Ltd (ASX:OSL) achieves significant clinical and financial milestones, expanding its global presence and enhancing its financial position in H1 2025.